Clinical Trial Update: Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum [Phase 1, Phase 2]

View source ↗

Summary

A single-arm clinical trial investigated the potential effect of secukinumab (anti-IL-17) in treating pyoderma gangrenosum; the study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Technical University of Munich | Conditions: Pyoderma Gangrenosum | Phase 1, Phase 2 | Status: COMPLETED